Sarah Kennedy: Calocurb CEO on Wegovy becoming available in New Zealand
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Sarah Kennedy: Calocurb CEO on Wegovy becoming available in New Zealand
-
Narrado por:
-
De:
Acerca de esta escucha
Access is opening up for Kiwis to a weight loss drug described as a game changer.
Wegovy, made by pharma-co Novo Nordisk, will arrive in pharmacies next week.
It's not funded by Pharmac, so users will have to pay and get a prescription for the weekly injectable.
Calocurb CEO Sarah Kennedy told Ryan Bridge that people need to be aware of both the cost of the drug and the side effect.
She says that over 70% of people using Wegovy will have gastrointestinal problems that range from nausea to diarrhoea, and over 70% of people regain the weight within a year.
Kennedy says lifestyle changes need to be made as well as taking the drug.
LISTEN ABOVE
See omnystudio.com/listener for privacy information.
Todavía no hay opiniones